Background: Guidelines suggest statin use after acute myocardial infarction (AMI) should be close to universal in patients without safety concerns yet rates are much lower than recommended, decline with patient complexity, and display substantial geographic variation. Trial exclusions have resulted in little evidence to guide statin prescribing for complex patients.
The reason for statin use rates being well below guideline recommendations does not appear to be insufficient evidence diffusion as an LDL-C of <100 mg/dL (defined as the goal of treatment in earlier US cholesterol guidelines 13 ) was identified by 96% of US physicians as the treatment goal for high-risk patients. 14 Alternatively, nonuniversal statin prescribing after AMI may reflect provider beliefs that statin benefits and risks are heterogenous across patients and that the statin prescribing in practice is being individualized to patient circumstances. Randomized controlled trial (RCT) evidence supports the idea that absolute risk reductions from statins may be heterogeneous across patients with respect to factors such as diabetes or heart failure. [15] [16] [17] [18] In addition, although the rate of statin-related adverse events reported in RCTs were low, adverse events appear more often in practice and vary with statin intensity, patient age, sex, weight, health behaviors, comorbidities, and concomitant drug use. [19] [20] [21] [22] [23] [24] [25] If providers are trying to limit statin prescribing to only those patients for whom they believe statin benefits outweigh risks, the relevant policy question then becomes whether statin-use rates after AMI represent an optimal sorting of statins across patients. Are existing rates "right"? 26 If present statin-use rates are less than optimal, higher rates should yield survival gains sufficient to outweigh additional adverse effect risks and treatment costs. Conversely, if statin-use rates after AMI are optimal, higher rates could result in higher health care costs and higher adverse effect rates with little added survival benefit. Estimates of the benefits and risks of statins for AMI patients on the "extensive margin" [27] [28] [29] are needed to address this question. AMI patients on the extensive margin can be thought of as those who would be next to receive a statin if use rates increased, or those first not to receive a statin if rates were lowered.
The objective of this paper is to use the variation in statin practice styles for Medicare AMI patients across local areas found in earlier research 11 to assess the benefits and risks of statins for patients on the extensive margin. We use instrumental variable (IV) estimation methods to assess the effects of higher use rates of both lower intensity and highintensity statins after AMI on survival rates, adverse event rates, and health care costs. IV estimators yield estimates that are properly generalized to the subset of patients whose treatment choices were influenced by the instrument used in the study. 30, 31 Here we use instruments derived from the variation in statin practice styles across local areas so that our estimates can be interpreted tangibly as what might be expected from interventions targeted at changing statin-use rates. Separate IV analyses are performed for complex patient subgroups because statin rates have been observed to vary with complexity.
METHODS

Data and Study Cohort
Medicare claims files and enrollment information for all Medicare beneficiaries with an AMI in 2008 and 2009 were obtained based on the Chronic Condition Data Warehouse (http://www.ccwdata.org) definition of AMI (an inpatient claim with the primary diagnosis code 410.x1). The study cohort contained all AMI Medicare patients with sufficient fee-for-service coverage to enable proper measurement of study variables. The online appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A861 contains a full description of the exclusion criteria used. The final cohort contained 124,813 patients. In addition, because statin use after AMI was found to vary substantially with patient complexity, we stratified the cohort based on prior heart failure (N = 66,644), prior chronic kidney disease (N = 43,690), prior diabetes (N = 54,125), and patients with none of these 3 conditions before AMI admission (N = 31,170).
Treatment Variables
Two binary statin treatment variables (lower intensity and high-intensity) were specified for each patient to represent statin availability for use in the month after AMI discharge. High-intensity statins were defined as those that can lower LDL-C by 50% or more: atorvastatin 40, 80 mg; and rosuvastatin 20, 40 mg. Lower intensity statins were defined as those that lower LDL-C <50%: atorvastatin 10, 20 mg; fluvastatin 20, 40, 80 mg; lovastatin 10, 20, 40, 80 mg; rosuvastatin 5, 10 mg; pravastatin 10, 20, 40, 80 mg; and simvastatin 5, 10, 20, 40, 80 mg. 32 The online appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/ A861 provides the approach used to measure these binary variables using Medicare Part D event data.
Outcome Variables
This study focused on 4 separate outcomes: 1-year survival; 1-year cardiovascular event-free survival; 1-year occurrence of any adverse event found to be associated with statins in previous population studies 24, 25 (muscle-related inpatient and outpatient events; inpatient acute renal events, or inpatient acute hepatic events); and 1-year total health care cost from the perspective of the Medicare program. Secondarily, the 1-year occurrence of each distinct adverse event were analyzed. The online appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A861 describes the approaches used to measure study outcomes and the ICD-9 codes and Medicare claims files used.
Covariates
A list of the covariates specified in all estimation equations can be found in the online appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A861. Full definitions of these variables can be also found in a previous publication. 11 
IV Strategy
A linear 2-stage least squares IV estimator with robust SEs was used to estimate the absolute effect of statins on each study outcome. STATA software was used. Linear 2-stage least squares yields consistent estimates of absolute treatment effects on outcomes for the group of patients whose treatment choices were influenced by the instrument specified regardless of the underlying error distributions. Further justification for this estimator can be found in the online appendix, Supplemental Digital Content 1, http:// links.lww.com/MLR/A861.
The instruments used in this study were measures of local area statin practice styles for the AMI patients living around the residence ZIP codes of the patients in our sample. We postulated that patients did not choose their residence in a manner related to unmeasured confounders for a future acute condition and that patients with an acute condition living in a local area with physicians having stronger preferences for a particular treatment are more apt to receive that treatment. A full description of the local area practice style measurement approach used here is documented elsewhere. 11 Briefly, local areas were constructed for each patient ZIP code by consecutively adding AMI patients from the next closest ZIP codes based on driving times until at least 150 patients were found. 33 Robustness checks for alternative local area sizes were performed. For the patients in the local area around each ZIP code, area treatment ratios (ATRs) for "no statin," "lower intensity statins," and "highintensity statins" were calculated as the ratio of the number of patients in the local area who received each respective statin intensity over the sum of the predicted probabilities across these patients of receiving that statin intensity. This approach to measure local area practice styles was found to explain a larger portion of treatment variation than other local area definitions and effectively balance measured covariates. [33] [34] [35] RESULTS Table 1 provides average characteristics for our sample when patients are grouped by (1) post-AMI statin intensity and (2) the quintiles of the local ATR for "no statins." Patients using either a high or lower intensity statin after AMI relative to patients without a statin were more likely younger, male, and living in a ZIP code that was metropolitan with a higher than average income and a higher than average life expectancy. Statin users also had fewer comorbidities as measured by the Charlson Score, 37 had fewer prior conditions related to adverse events, were more likely to have used a statin previous to their AMI, and more likely to have been initially prescribed other drugs. Statin users had characteristics suggestive of more serious AMIs (more likely arterial wall, ST-elevation, and received cardiac catheterization) than nonusers. Statin users had higher unadjusted 1-year survival and cardiovascular event-free survival rates, lower 1-year acute renal and 1-year muscle-related event rates, and lower 1-year Medicare costs than nonusers. In addition, lower intensity statin users had lower unadjusted 1-year hepatic event rates than nonusers.
Comparisons across ATR quintiles provide some evidence as to whether our instruments provide a "natural experiment" in statin use. In the first quintile, 32.4% of patients had no statin available for use within 30 days of AMI discharge (67.6% had a stain available) compared with 43.6% of patients in the fifth quintile (56.4% had a stain available). Although trends in several measured covariates across quintiles reached statistical significance, for the most part these differences were modest compared with when patients were grouped by statin use. Exceptions were mainly for demographic and socioeconomic characteristics. Local areas with higher statin use (eg, quintile 1) had higher percentages of African Americans, patients who lived in a metropolitan area, and patients who lived in a ZIP code with a higher than average income than the other quintiles. No trends in unadjusted survival or Medicare cost were observed across quintiles. Unadjusted adverse event rates fell as statin-use rates fell moving from quintiles 1 to 5. Table 2 contains average unadjusted 1-year outcomes for the full sample and by patient complexity. The adverse event rates for our population were much greater than what was reported for younger and less complex patients using statins. 24 Survival and cardiovascular event-free survival rates were lower in the complex patient subsets compared with the noncomplex subset while Medicare costs and adverse event rates were higher in these subsets. Table 3 summarizes our IV results for the full sample and subsets based on complex conditions. Alternative representations of Table 3 based on local areas using 100-patient and 200-patient thresholds around patient residence ZIP codes are available in the online appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A861. For each cohort, each row of Table 3 provides estimates by statin intensity. Column 1 shows the percentage of patients using statins by intensity level and the interquintile range of these percentages across local area practice style quintiles. Estimates of the absolute effect of statin use on each outcome should be interpreted in terms of statin rate changes only within these ranges. Column 2 contains the F-statistics testing whether the instruments had statistically significant impacts on lower intensity and high-intensity statin use. 38 The instruments had statistically significant impacts on both lower and high-intensity statin use for the full sample and within each complexity subset. Columns 3-9 contain the absolute effect estimates of statin use by intensity on each study outcome relative to no statin. For example (0.081) is the absolute effect estimate of lower intensity statin use on 1-year survival for the marginal patients within the full sample relative to no statin. This result can also be interpreted as follows: a 1 percentage point increase in the use of lower intensity statins within the range of 43%-57% (eg, increasing the lower intensity percentage from 50 to 51) was associated with an 0.081 percentage point increase in 1-year survival (eg, 85.4-85.481) relative to no statin. The same 1 percentage point increase in lower intensity statin use within this range led to an average decrease in Medicare costs for marginal patients of $2370. Across the full sample, higher statin-use rates were associated with higher 1-year survival and cardiovascular event-free survival rates (columns 3-4) with high-intensity statins showing greater additional survival benefit from higher use rates than lower intensity statins. Higher statin-use rates in the full sample were also associated with higher adverse event rates (columns 5-8) with high-intensity statin-use rates being positively associated with higher rates of all 3 adverse advents. Column 9 shows that average Medicare costs per marginal patient were reduced with greater statin-use rates but this association was only statistically significant for lower intensity statins.
The statin treatment effect estimates stemming from rate differences across local areas varied with patient com- Cochran-Armitage 2-sided test of trend in characteristic value across patients grouped into quintiles based on local area high-intensity practice style measure. For example, the P-value for age 76-85 tests whether a linear trend in the percentage of patients in this age group exists across quintiles of the high-intensity ATR-based patient groups. On the basis of area treatment ratio (ATR) of actual "no statin" treatment rate over predicted "no-statin" treatment rate for the 150 AMI patients living closest to a patient residence ZIP code.
y On the basis of highest statin intensity available to patients in 30 days after AMI discharge. plexity. AMI patients with no prior heart failure, no chronic kidney disease, and no diabetes had the highest use rates of both lower intensity and high-intensity statins. For this subset higher rates of high-intensity statin use were associated with survival gains and the absolute effect of this association was about half of what was found for the full sample. No statistically significant associations with other study outcomes were found for this patient subset. Statin-use rates were lower for complex patients as compared with noncomplex patients. Complex patients had larger increases in 1-year survival and 1-year cardiovascular event-free survival rates associated higher statin-use rates than noncomplex patients. Conversely, higher statin-use rates for complex patients were associated with higher adverse event rates than for noncomplex patients. Statin-use rates regardless of intensity were positively associated with acute hepatic events in each complex patient subset. Use rates of high-intensity statins were positively associated with acute renal event rates in each complex patient subset. Higher statin-use rates did not have statistically significant associations with muscle-related adverse effects in any patient subset, but the estimates for these conditions were generally higher for complex patients than noncomplex patients. In addition, higher statin-use rates among complex patients were associated with larger reductions in 1-year Medicare costs than among noncomplex patients. For patients with prior heart failure Medicare cost reductions of over $4000 were found associated with greater statin-use rates for either statin intensity level.
DISCUSSION
Our results provide strong evidence that providers were attempting to individualize statin prescribing to patients after AMI. Statin users after AMI were less complex, had higher rates of prior statin use, and lower rates of prior hepatic, renal, and muscle-related events as compared with the patients without a statin after AMI. In addition, statin users had lower unadjusted 1-year post-AMI rates of acute renal events and muscle-related events than nonusers. Lower intensity statin users also had lower post-AMI 1-year rates of acute hepatic events than nonusers. Because statins are not considered protective with regard to these conditions, these unadjusted outcome comparisons suggest that providers purposely restricted statins from patients who were at higher risk of these adverse events. Table 4 summarizes our results with regard to changes in statin-use rates after AMI. For the noncomplex patients in our study high-intensity statin-use rates were positively associated with 1-year survival with no additional adverse event risk. These estimates are consistent with the 2013 ACC/AHA cholesterol guidelines in that patients should be on a high-intensity statin if safety concerns are not present. 7 These guidelines were based on RCTs and meta-analyses of RCTs that showed survival gains and cardiovascular eventrisk reductions from statins with few reported adverse events. 39, 40 The noncomplex patients in our sample were most closely aligned to the populations in these studies.
In contrast, outcome tradeoffs were associated with higher rates of statin use for the complex patients in our study. On average statin use rates were lower for complex patients than noncomplex patients. From these lower average rates, higher statin use rates for complex patients were associated with larger survival and cardiovascular event free survival rate increases than what was observed for noncomplex patients. These statin benefits were tempered by larger positive associations between statin-use rates and adverse event rates than what was observed for noncomplex patients. Across the 3 complex patient subgroups, a 1 percentage point increase in statin-use rates was associated with between a 0.095 and 0.176 increase in the proportion of patients with acute hepatic events over the next year, depending on statin intensity. Likewise, a 1 percentage point increase in high-intensity statin-use rates was associated with a 0.138-0.178 increase in the proportion of patients with acute renal events over the next year. Although no estimate for muscle-related adverse events was statistically significant within any complex patient subset, a positive association between high-intensity statin availability and muscle-related events over the entire sample seems to emanate from the associations seen within the complex patient subsets. The 2013 ACC/AHA cholesterol guidelines are clear that safety concerns should be considered in the statin prescribing decision. The practice patterns we observed for complex patients may reflect provider attempts to incorporate safety concerns into practice in light of the limited CKD indicates chronic kidney disease; Diab, diabetes; HF, heart failure. *P < 0.05. **P < 0.01. ***P < 0.001.
RCT evidence available for complex patients. Indeed, the patients represented in the statin RCTs had far fewer complexities than the patients in our Medicare sample. Moreover, even the few statin RCTs that included more complex patients still had exclusions based on liver function, renal impairments, and muscular problems. 41, 42 Our study provides important new evidence of the statin side effect risks for older complex patients.
It is important to understand that our estimates should be generalized only to patients within each complex subset whose statin use would have changed had they resided in a local area with different statin prescribing preferences. The interquartile ranges in statin-use rates in Table 3 are the ranges within which our results should be interpreted. Extrapolating our estimates outside these ranges is problematic if statin recommendations were individualized across patient-based expected benefits and risks and our evidence suggests that providers were attempting to individualize statin use across patients. Consequently, our estimates only inform the discussion of whether existing statin-use rates should change within a window around the rates observed in 2008-2009 and not a discussion of whether statins should or should not be used generally within each patient subset defined by complexity.
It should also be emphasized that validity of our estimates is based on the assumption that local area statin practice styles are not associated with unmeasured factors related to study outcomes. This assumption is supported by previous research showing local area statin practice styles varying substantially across and within states 11 and that grouping patients by local area practice styles substantially reduced the imbalance in most measured clinical covariates as compared with grouping patients by actual statin use. However, grouping patient by local area practice styles did exacerbate the imbalance in some demographic and socioeconomic variables relative to grouping patients by statin use. Although these factors were controlled for directly in our analysis, they could be symptomatic of other unmeasured differences across local areas that may confound our results. For example, if statin use and unmeasured health care access were positively correlated it is possible that higher adverse event rates in areas with higher statin use are partially attributable to reporting bias. Patients with greater access to health care may have greater opportunities to be diagnosed with adverse events. It is also possible that local area statin rates could be positively correlated with local area use of other types of aggressive care we have not measured. Table 1 shows a slight positive relationship between local area statin rates and rates of beta blockers and renin-angiotensin system antagonists after AMI. Although we controlled for the use of these drugs directly in our analysis, our results could be partially attributable to correlations with other unmeasured treatments. However, if unmeasured confounders were the predominant source of our estimates we would expect to find higher adverse event rates associated with statin use across all complex patient subsets, rather than the specificity of the association for complex subsets only.
Statins are advocated for use after AMI with a proviso for safety concerns. RCT evidence suggests that statin safety concerns are minimal that has led some to believe that statin prescribing post-AMI should be close to universal and behavioral interventions be used to increase statin initiation. 12 However, statin RCTs have generally excluded the most complex patients. Our study shows that most elderly AMI patients within Medicare are complex and would have been excluded from these trials and that providers have been individualizing statin use across Medicare patients based on perceived risks of adverse events that have not been observed in published evidence. Complex patients had lower statin-use rates than noncomplex patients and the effects of higher statin-use rates on benefits and risks varied with patient complexity. Higher rates of high-intensity statin use for noncomplex AMI patients was associated with higher survival rates with no additional adverse event risk which is consistent with RCT evidence. In contrast, for complex patients who are unrepresented in the RCTs we showed that higher statin-use rates involves tradeoffs between survival benefits and adverse event risks. Because of these tradeoffs, the "right rate" of statin use by complex patients remains unclear. Nonetheless, our evidence suggests that promoting universal statin use among complex AMI patients over observed practice without consideration of the potential of safety issues may not be a wise policy. 
